undamentalytics Newsletter

Kenvue revenue

Kenvue's revenue was $15.12bn in fiscal 2025, down 2.1% on the year before. Since fiscal 2021 ($15.05bn) it has grown at a compound 0.1% a year. Over the last twelve months it was $15.53bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kenvue: revenue history, annual
Fiscal year2021Jan 20222022Jan 20232023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue15.115.015.415.515.115.5
Growth on the year before—−0.7%+3.3%+0.1%−2.1%—
Gross profit8.48.38.69.08.89.1

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 28, 2025
Segments
Line of business Revenue Share YoY
Self Care $6.4B 42.2% ▼ 2.3%
Essential Health $4.6B 30.6% ▼ 1.2%
Skin Health and Beauty $4.1B 27.2% ▼ 3.0%
Geography
Region Revenue YoY
North America $7.3B ▼ 4.2%
United States $6.5B ▼ 3.9%
EMEA $3.7B ▲ 4.6%
Asia Pacific $2.8B ▼ 6.7%
Latin America $1.4B ▲ 1.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Kenvue's 10-K filed February 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Personal Care Products: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kenvue $15.53bn 3.5% -0.0%
The Estée Lauder Companies $15.28bn 5.8% -0.5%
Coty Inc. $5.81bn -1.5% 1.5%
Herbalife LTD. $5.28bn 6.4% 1.6%
Procter & Gamble $87.92bn 3.5% 1.8%
Bellring Brands, Inc. $2.35bn 5.9% 14.4%

Compare with peers

Head to head: EL vs KVUECOTY vs KVUEHLF vs KVUEKVUE vs PG

More: Personal Care Products stocks compared, Consumer Staples sector, rankings of US companies

Figures from Kenvue's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kenvue.